Purpose The object of this study was to assess whether 18 Ffluorodeoxyglucose PET/CT (FDG PET/CT) provides novel information in patients with Takayasu's arteritis (TA) in addition to that provided by current activity assessment, to analyse the effects of possible confounders, such as arterial grafts, and to verify whether PET/CT could be informative in lesions <4 mm thick. Methods We studied 30 patients with TA, evaluated from October 2010 to April 2014 by both PET/CT and magnetic resonance imaging (MRI). All arterial lesions were evaluated by PET both qualitatively (positive/negative) and semiquantitatively (maximum standardized uptake value, SUV max ), and the thickness of lesions in the MRI field of view was evaluated. In a per-patient analysis, the relationships between the PET data and acute-phase reactants and NIH criteria for active TA were evaluated. In a per-lesion analysis, the relationships between the PET features of each lesion and MRI morphological data were evaluated. The effects of the presence of arterial grafts were also evaluated.
Introduction
Takayasu's arteritis (TA) is a chronic-relapsing systemic inflammatory disease of unknown aetiology, typically affecting women less than 40 years of age [1, 2] . The central feature of TA is granulomatous inflammation and wall thickening of large arteries [1, 2] , with subsequent remodelling with stenoocclusions or ectasia/aneurysms. The first goal of TA therapy is to prevent vascular progression [3] . Unfortunately, vascular progression is difficult to predict and disease activity assessment remains an unresolved conundrum. Acute-phase reactants such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) do not accurately reflect disease activity [4] [5] [6] . To guide therapeutic decisions multi-item disease activity criteria have been proposed, for example the National Institutes of Health (NIH) criteria [4, 7] and the Indian Takayasu's arteritis activity score [8] . Despite the use of these criteria, 44% of patients thought to be in clinical remission have histological evidence of active arterial inflammation, and 61% develop new arterial lesions [4, 9] . Local inflammation as well as tissue remodelling are increasingly recognized as a central pathogenic component in largevessel vasculitis [10] . Consistent with this, levels of locally produced long pentraxin-3 apparently discriminate vascular events such as inflammation and progression better than ESR and CRP [11] .
New fundamental markers are thus urgently needed to characterize the events in the arterial wall niche, and noninvasive analysis of the arterial wall by functional imaging might be a tool that meets this need. In particular, integrated positron emission tomography/computed tomography (PET/CT) combining functional (PET) and morphological (CT) information provides precise anatomical definition of metabolic activity with an increased sensitivity for arterial wall inflammation. This facilitates diagnosis of TA in the early phase before significant arterial remodelling has occurred [12] .
The PET tracer 18 F-fluorodeoxyglucose (FDG) accumulates in metabolically active cells, including activated leucocytes, at the site of tissue injury. FDG PET/CT is useful for the diagnosis of large-vessel vasculitis in patients with a smouldering clinical presentation [12] [13] [14] [15] [16] [17] [18] [19] . Besides diagnosis, the role of PET/CT in the follow up of TA patients is still do be defined, as controversial results have been reported [12, 15, 18, [20] [21] [22] [23] [24] . Heterogeneity among studies in terms of assessment of arterial uptake and definition of positive uptake is substantial, with frequent alternative use of qualitative (e.g. visual grade) and semiquantitative (e.g. maximum standardized uptake value, SUV max ) measurements, making comparisons often noninformative. Moreover, it is still unknown whether PET/CT can predict progression of vascular involvement. TA lesions are typically a few millimetres thick. It is well known that PET/CT imaging suffers from significant limitations related to partial volume effects and to the low resolution of PET [25] . Therefore, PET/CT might be less informative in patients with thinner arterial lesions. However, to the best of our knowledge, little is known about the potential bias associated with the size of arterial lesions in terms of wall thickness.
In the study presented here the inflammation within thickened TA arteries was evaluated by FDG PET/CT to determine whether this technique provides novel information in addition to acute-phase markers and multi-item disease activity criteria. Potential confounding factors, including the presence of arterial grafts and lesion thickness, were also explored.
Materials and methods

Patient selection and evaluation
Thirty consecutive patients satisfying the American College of Rheumatology classification criteria for TA [26] , who had undergone at least one FDG PET/CT scan at San Raffaele Scientific Institute from October 2010 to April 2014, were retrospectively enrolled. The FDG PET/CT scans were performed as part of routine follow-up to monitor disease activity and response to therapies. Patients were treated according to clinical need. Additional eligibility criteria were: (1) availability of magnetic resonance imaging (MRI) findings; (2) availability of laboratory data (including acute-phase reactants) and clinical data (including treatment and disease activity evaluated according to NIH criteria) obtained at the time of the FDG PET/CT scan; (3) written informed consent for anonymous publication of disease-related information according to the principles of the Declaration of Helsinki. Patients with proven or suspected ongoing infection were excluded.
C R P w a s m e a s u r e d u s i n g a l a t e x -e n h a n c e d immunoturbidimetric assay (ADVIA Chemistry System; Bayer Healthcare AG, Leverkusen, Germany). ESR was evaluated using the Westergren method [27] . The local laboratory normal standard ranges were 1-20 mm/h for ESR and <6 mg/ L for CPR. MRI was performed a median of 1 month before or after FDG PET (range: 0-11 months). Patients were divided into two groups according to validated NIH criteria: patients with clinically active disease and patients with clinically inactive disease.
PET/CT imaging technique
Whole-body PET/CT was performed with a Discovery ST-STE-PET/CT 690 scanner (GE, Milwaukee, WI) following a standard clinical protocol [28] . Patients fasted for more than 6 h, and the blood glucose level before injection of approximately 370 MBq of FDG was confirmed to be less than 150 mg/dL in all patients. A whole-body emission scan was obtained in all patients 60 min after injection using the multiple bed position technique. CT data were used for attenuation correction and image fusion. PET data were reconstructed iteratively with attenuation correction, and axial, sagittal and coronal slices were generated. PET images were used for assessment of disease activity and fused PET/CT images were used for localization.
Analysis of PET/CT images
FDG PET/CT scan images were displayed in coronal, transaxial and sagittal planes, and as rotating 3D images. Images were reviewed by two independent nuclear medicine physicians who were blinded to the patient's clinical disease activity. In cases of discrepancy, the final interpretation was determined by consensus between the two physicians after an additional review. All vascular lesions on FDG PET/CT were evaluated both qualitatively (visual analysis) and semiquantitatively (SUV max ).
Visual analysis (positive/negative on FDG PET/CT) of a previously defined set of arteries was performed, including the abdominal aorta, ascending aorta, aortic arch, descending thoracic aorta, subclavian artery, axillary artery, brachiocephalic trunk (innominate artery), humeral artery, renal artery, common iliac arteries, common carotid arteries, femoral arteries and popliteal arteries. Focal uptake in the arterial wall was graded in relation to the uptake in the liver as grade 0 (no vascular uptake or uptake lower than in the liver) and grade 1 (vascular uptake similar to or greater than in the liver). Grade 1 vascular uptake was considered to be significant, and the scan was considered positive if at least one arterial lesion showed significant uptake [29] . For the determination of SUV max , a volume of interest was drawn manually on the vessel uptake site and SUV max was defined as the highest uptake value in this volume. Thus, in a per-lesion analysis each lesion was characterized in terms of its SUV max , while in a per-patient analysis, SUV max was defined as the highest SUV max of the lesions of the patient, as in previous studies [29] .
To understand the clinical meaning of PET/CT characterization of vasculitic lesions, we considered potential confounders that might influence PET/CT results independently of the local disease status, such as the presence of arterial grafts [30] and lesion dimensions. Considering the spatial resolution of state-of-the-art PET scanners and the thickness of the arterial lesions in our population, we established an arbitrary cut-off of 4 mm for defining a thick lesion.
MRI
Morphological data relating to lesion thickness were obtained from MRI studies [31] performed using a 1.5-T MRI wholebody scanner (Achieva Nova Master; Philips Medical System Best, The Netherlands) with a dedicated phased array head and neck coil or a dedicated phased array thoracic coil. Morphological sequences were applied to evaluate vessel wall thickening. First-pass dynamic MRI sequences targeting the thoracoabdominal aorta and the supraaortic trunks were applied during contrast medium infusion (Gadovist®, 1 nmol/ mL; Bayer Schering Pharma Berlin, Germany). Highresolution sequences were applied before and after contrast medium administration. These sequences allow the evaluation of wall thicknesses up to 1 mm of the vessel included in the field of view, which notably excluded the lower limbs. The iliac arteries were included in the field of view only in patients with significant thoracoabdominal disease. In the per-patient analysis, the maximal thickness of the lesions included in the field of view of the MRI study was determined in each patient.
The pulmonary artery and the aortic root were not characterized, because of the blurring caused by heart motion.
Statistical analysis
Both the per-patient and the per-lesion analyses were performed with and without exclusion of lesions with arterial grafts. Continuous variables were considered to have a non-normal distribution and are expressed as median values and ranges. The Mann-Whitney test was used to compare continuous variables between two unrelated groups, while nonparametric correlations were evaluated with Spearman's rank correlation coefficient (rho). Associations were evaluated with the chi-squared test or Fisher's test. The per-patient Tables 2 and 3 , respectively. PET and MRI combined revealed a total of 176 lesions, and 154 of these were included in the field of view of the MRI scans and were studied with both techniques. The median thickness of these lesions was 2 mm (range 1.0-10.0 mm).
Only a subset of arterial lesions shows significant FDG uptake
In the per-patient analysis ( Table 2 ), 16 of the 30 patients (53%) had at least one arterial lesion with FDG uptake equivalent to or greater than uptake in the liver; in the remaining 14 patients, PET/CT was negative. The patients showed a median SUV max of 0.1 (range 0.1-9.8). In the per-lesion analysis, 46 of 176 lesions (26%) evaluated by PET/CT showed significant FDG uptake (Table 3 ). The most frequent sites with significant FDG uptake were the ascending aorta/aortic arch (14 lesions, 30%), the abdominal aorta (6, 13%) and the common carotid arteries (7, 15%). These results clearly show that FDG uptake is present in only some arterial lesions and can be used to characterize and differentiate arterial lesions (Figs. 1 and 2) . To understand the clinical relevance of this finding, we analysed the determinants of FDG arterial uptake on PET/CT.
Determinants and confounders of FDG arterial uptake: arterial grafts and lesion thickness
Periprosthetic FDG uptake may be nonspecific [30] . Seven patients had undergone arterial insertion of 11 grafts. PET/ CT was performed 37 months (range 12-55 months) after surgery. Ten of these 11 grafts showed significant FDG uptake. Of the 11 grafts, 7 involved the ascending aorta, 1 the aortic arch, 1 the abdominal cavity, and 2 the iliac arteries. The median SUV max of grafted lesions was 3.9 (range 0.1-6.7) and the median wall thickness was 3.5 mm (range 1.0-4.0 mm). In three of the seven patients (10% of the 30 patients) only the graft sites showed significant FDG vascular uptake, and in five patients (17% of the 30 patients) the graft sites showed the highest SUV max . Hence, graft sites were excluded from subsequent per-patient and per-lesion analyses. After excluding grafted lesions to avoid the potential bias related to possibly nonspecific FDG uptake, significant uptake was still detectable in 13 of the 30 patients (43%; Table 2 ) and in 36 of 165 lesions (22%; Table 3 ). Lesion size might also be a potential confounder. No correlation between maximal lesion thickness and SUV max was observed in the per-patient analysis (rho 0.210, p = 0.265; Table 2 ) or in the per-lesion analysis (rho 0.053, p = 0.530; Table 3 , Fig. 3 ). However, when considering lesions with significant FDG uptake only, a correlation between maximal lesion thickness and SUV max was observed in the per-lesion analysis (rho 0.672, p = 0.002, per-lesion analysis; rho 0.269, p = 0.374, per-patient analysis). Of the 39 lesions with significant FDG uptake, 15 (38%) were <4 mm thick, and 8 (21%) were <2 mm thick, suggesting that even small arterial lesions can be characterized by PET/CT.
Next the 12 patients (40%) with at least one lesion ≥4 mm thick as assessed by MRI were analysed separately (Table 4) . After exclusion of grafted arteries, 5 of the 12 patients (42%) had a positive scan (significant uptake in at least one arterial lesion). Of 29 lesions ≥4 mm thick, 5 (17%) showed significant uptake (Table 5) . Thus, the presence of arterial grafts and lesion thickness do not account for the entire variability seen in the results obtained by FDG PET/CT.
FDG PET/CT reflects the fundamental characteristics of TA lesions in contrast to systemic inflammation markers and disease activity criteria
Values of SUV max were similar in patients treated or not treated with steroids, and non-biological or biological immunosuppressive agents (data not shown). Rather unexpectedly, increased FDG uptake on PET/CT in arterial lesions did not necessarily identify patients with a greater extent of systemic inflammation. CRP levels and ESR were similar in patients with and without significant FDG uptake, even after exclusion of grafted lesions from the analysis (Fig. 4, Table 6 ). Moreover, neither CRP levels nor ESR was correlated with the number of lesions with significant uptake on visual analysis (rho −0.134, p = 0.480, and rho −0.156, p = 0.409, respectively) or with the SUV max (rho −0.117, p = 0.537, and rho −0.114, p = 0.549, respectively; Table 7 ). Similar results were obtained when grafted lesions were included in the analysis, and in the subset of patients with at least one lesion with a thickness ≥4 mm (data not shown).
Furthermore, FDG uptake did not differ in patients with active TA identified using the NIH criteria (Table 8) 
Discussion
Additional characterization of the events occurring at disease sites in the arterial wall is a major unmet need in TA. In this investigation of the possible role of FDG PET/CT in the follow-up of patients, we found first that FDG PET/CT reveals unique and fundamental features of arterial involvement in TA, second that arterial grafts influence FDG uptake as assessed by PET/CT, and third that lesion dimensions in terms of wall thickness may be another confounder, but FDG uptake on PET/CT is detectable even in lesions <4 mm thick.
Previous studies have shown variable degrees of association between TA activity and FDG PET/CT findings [12, 15, 18, [20] [21] [22] [23] [24] . Increasing data suggest the importance of overcoming a Bsystemic inflammation only^view of TA [3, 32] that considers local inflammation and vascular remodelling. We found that FDG PET/CT is a novel approach to the characterization of arterial involvement in TA that reflects fundamental features of the lesions in contrast to acute-phase reactants and NIH activity criteria. This finding supports the observation that vascular events in the arterial wall niche occur independently of systemic inflammation. Thus, according to the Outcome Measures in Rheumatology (OMERACT) Ultrasound Task Force, new outcome measures are needed for monitoring TA patients in clinical practice and research studies [33] .
In the present study, we also evaluated the potential impact on FDG PET/CT results of two possible confounding variables, that is the presence of an arterial graft and the effect of lesion dimensions in terms of arterial wall thickness. It has been reported that arterial grafts of foreign material are frequently sites of significant FDG uptake, even long after surgery [30] . We found that grafted arteries in TA patients were frequently the sites of maximal FDG uptake within the arterial tree, sometimes representing the only FDG-positive lesions. Restenosis after surgical grafting is more frequent in TA than in other noninflammatory arterial diseases [3] . This study was not designed to assess whether uptake at graft sites is nonspecific or alternatively reflects vascular remodelling. Until further prospective studies clarify this issue, we believe that grafted arteries should be reported separately from native arteries in the clinical setting.
With regard to the other confounder (the effect of lesion dimensions in terms of wall thickness), it is well known that the original diameter of the involved artery and the lesion thickness are important factors, due to partial volume effects and the intrinsic limitations of PET/CT [25] . Indeed, FDG PET/CT cannot characterize the wall of small arteries. In the present study, we found that some lesions <4 mm thick had a metabolic activity high enough to be detectable by PET/CT. Thus, even thinner lesions could be characterized by their FDG uptake on PET/CT, although a formal comparison between lesions of different thickness is impossible in vivo. It is logical to speculate that the accuracy of PET/CT might be lower in smaller lesions, and correction for the partial volume effect [25] might be particularly helpful in these cases. It is hypothesized that the intrinsic features of arterial wall inflammation in thin and thick arterial lesions may result in an association between FDG uptake and lesion thickness. However, a significant correlation between SUV max and lesion thickness was not found when all 149 lesions and 144 nongrafted lesions were studied, but was found when the analysis was restricted only to FDG-avid lesions. This suggests the importance of other determinants of FDG arterial uptake in addition to lesion thickness. However, acute-phase reactants and disease activity as assessed by NIH criteria did not correlate with vascular FDG uptake even when a subgroup of patients with at least one lesion of thickness ≥4 mm was analysed. These data strongly support the contention that FDG PET/CT reveals unique features of arterial lesions and provides fundamental lesion characterization in contrast to systemic inflammation and disease activity. Moreover, they argue against the possibility that FDG PET is informative in a subgroup of patients only (e.g. those with thick arterial lesions). Moreover, vascular remodelling, possibly identified by increased FDG uptake, may not only result in progression of arterial involvement, but also represent a protective mechanism to restore vessel integrity in presence of chronic injuries. Indeed, reverse remodelling has been reported after resolution of arterial inflammation [34, 35] . It cannot be excluded that the activity of protective and reparative mechanisms may be an additional cause of significant FDG uptake within arterial lesions, partially explaining the limited association between disease activity and PET results. Prospective studies are needed to address this issue.
Our study had some limitations. Firstly, it had a retrospective design, which may have predisposed to selection bias and suboptimal data collection, as the FDG PET scan was performed at different times after the onset of targeted treatments.
Secondly, drug therapy was not uniform, with many patients receiving biological agents. An interesting issue is the demonstration of the value of combining functional PET data with morphological data derived from MRI. In the future, the combination of FDG PET and MRI in terms of hybrid PET/MRI compared with PET/CT may offer both high-resolution imaging of anatomical features in a single examination and additional specific sequences that allow the detection of more subtle vessel wall changes, while also resulting in lower patient radiation exposure when compared to PET/CT [36] [37] [38] .
Conclusion
FDG PET/CT reveals unique features associated with arterial involvement in TA: characterization of arteries by PET/CT provides information additional to systemic inflammation and multi-item activity criteria, and this is not limited to patients with the thickest arterial lesions. Therefore, FDG PET is a promising candidate disease marker that should be evaluated in future prospective studies, underlining the importance of local factors within the arterial niche in TA. Arterial grafting predisposes to periprosthetic FDG uptake whose significance is currently unclear. Thus, grafted and nongrafted lesions should be separately assessed both in clinical and in research settings.
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